File Download
  Patent History
  • Application
    PC T/CN2014074874 2014-04-07
  • Publication
    WO 2014161509 2014-10-09
  Patent Family
Supplementary

granted patent: NOVEL PD1 ISOFORMS, AND USES THEREOF FOR POTENTIATING IMMUNE RESPONSES

TitleNOVEL PD1 ISOFORMS, AND USES THEREOF FOR POTENTIATING IMMUNE RESPONSES
Priority Date2013-04-05 US 12/1808993P
Inventors
Issue Date5-Nov-2014
Citation
WO Patent WO 2014161509. World Intellectual Property Organization (WIPO), PatentScope, 2014 How to Cite?
AbstractIn one embodiment, the present invention provides a new isoform of human PD1 ([Delta]42PD1) that contains a42-nucleotide in-frame deletion located at exon 2 domain. [Delta]42PD1 does not engage PD-L1/PD-L2, and can induce the production of pro-inflammatory cytokines. In one embodiment, [Delta]42PD1can be used as an intramolecular adjuvant to develop a fusion DNA vaccine for enhancing antigen-specific CD8+T cell immunity and for prevention of pathogenic infection and/or cancer. In one embodiment, soluble [Delta]42PD1 protein could be a therapeutic target for autoimmune diseases. In other embodiments, proteins or peptides or nucleic acids encoding proteins or peptides containing [Delta]42PD1 could be used as immunogens for developing antibodies binding specifically to [Delta]42PD1. In yet another embodiment, neutralizing antibodies could block s[Delta]42PD1 function and accordingly could be used as treatment for autoimmune disorders.
Persistent Identifierhttp://hdl.handle.net/10722/206520

 

DC FieldValueLanguage
dc.date.accessioned2014-11-05T02:49:22Z-
dc.date.available2014-11-05T02:49:22Z-
dc.date.issued2014-11-05-
dc.identifier.citationWO Patent WO 2014161509. World Intellectual Property Organization (WIPO), PatentScope, 2014en_US
dc.identifier.urihttp://hdl.handle.net/10722/206520-
dc.description.abstractIn one embodiment, the present invention provides a new isoform of human PD1 ([Delta]42PD1) that contains a42-nucleotide in-frame deletion located at exon 2 domain. [Delta]42PD1 does not engage PD-L1/PD-L2, and can induce the production of pro-inflammatory cytokines. In one embodiment, [Delta]42PD1can be used as an intramolecular adjuvant to develop a fusion DNA vaccine for enhancing antigen-specific CD8+T cell immunity and for prevention of pathogenic infection and/or cancer. In one embodiment, soluble [Delta]42PD1 protein could be a therapeutic target for autoimmune diseases. In other embodiments, proteins or peptides or nucleic acids encoding proteins or peptides containing [Delta]42PD1 could be used as immunogens for developing antibodies binding specifically to [Delta]42PD1. In yet another embodiment, neutralizing antibodies could block s[Delta]42PD1 function and accordingly could be used as treatment for autoimmune disorders.en_US
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License for public patent documentsen_US
dc.titleNOVEL PD1 ISOFORMS, AND USES THEREOF FOR POTENTIATING IMMUNE RESPONSESen_US
dc.typePatenten_US
dc.identifier.authorityCHEN, ZHIWEI=rp00243en_US
dc.description.naturepublished_or_final_version-
dc.contributor.inventorCHEN, ZHIWEIen_US
dc.contributor.inventorCHENG, LINen_US
dc.contributor.inventorCHEUNG, KA LOON ALLENen_US
dc.contributor.inventorZHOU, JINGYINGen_US
patents.identifier.applicationPC T/CN2014074874en_US
patents.description.assigneeUNIV HONG KONG [CN]en_US
patents.description.countryWorld Intellectual Property Organization (WIPO)en_US
patents.date.publication2014-10-09en_US
patents.date.application2014-04-07en_US
patents.date.priority2013-04-05 US 12/1808993Pen_US
patents.description.ccwoen_US
patents.identifier.publicationWO 2014161509en_US
patents.relation.familyUS 2014302070 (A1) 2014-10-09en_US
patents.description.kindA1en_US
patents.typePatent_granteden_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats